make model chang incl new guidanc ad bgne deal updat
otezla neulasta enbrel biosimilar est new products/organ growth lead
ep rais ep
rais pt anticip bgne deal
dilut accret onward
new pt base ep driven solid top/bottom
rais pt rais sale estim enbrel otezla biosimilar
increas estim total product sale due
increas estim enbrel otezla biosimilar
partial off-set lower estim neulasta assum take
addit debt interest rate fund recent acquisit
otezla stake beigen expect neg impact ep
due increas interest expens share beigen loss new non-gaap ep
estim new pt employ price-to-earnings multipl
use multipl vs current year multipl yet believ
multipl expans warrant given strong ep growth driven solid
revenu growth net growth offer new organ product even
xgeva/prolia biosimilar acquisit otezla provid net increas sale
rel expect weak g-csf neulasta/neupogen esa epogen/aranesp
busi trade ep given higher ep growth
see case upsid possibl
amgen product revenu chang
cowen compani
pleas open note read impact bgne consolid amgn/revolut
pleas see page report import disclosur
like fundament due diversifi product mix biolog franchis
durabl protect product innov pipelin tight control opex
aggress cash return sharehold see near-term risk enbrel sensipar
gener challeng new product launch includ aimovig biosimilar
provid new growth prospect legaci franchis declin opinion amgen
continu provid sustain growth navig turbul water
legaci franchis erod meantim tezepelumab earli stage oncolog pipelin
gain visibl shore confid long-term prospect
potenti data
studi lung cancer
data tezepelumab studi
data bite
data omecamtiv mecarbil
studi heart failur
grow dividend consist stock
neulasta enbrel sensipar eros
less expect
aimovig biosimilar tezepelumab
tezepelumab success becom
revenu growth greater
pipelin contribut substanti
valu model
biosimilar launch exceed
neulasta rapid share loss sensipar
tezepelumab drug
aimovig slow
fail rais dividend pursu
success navig biosimilar competit legaci franchis
still contend patent challeng age brand nevertheless tight opex
control margin expans stock buyback new product launch ep growth
resili manag grow dividend annual major brand includ enbrel
sale neulasta denosumab franchis brand xgeva cancer
prolia osteoporosi sale aranesp/epogen like
tezepelumab asthma earli stage oncolog pipelin solid liquid tumor
biosimilar franchis aimovig also provid attract growth venu
